*****
Summary of Transcript:
In this podcast episode, the hosts discuss a recent study about semifluid and its effectiveness in weight reduction. They provide background information on insulin and glucagon and how they relate to the incretin effect. They explain the incretin effect, a difference in how oral and intravenous glucose is processed, and how it impacts insulin and glucagon levels. The hosts use graphs to illustrate the differences in glucose, insulin, and glucagon levels between oral and intravenous glucose administration. They then discuss how semifluid works as an analog of GLP-1 and its potential as a drug for obesity. Overall, the episode provides a detailed explanation of the study and its implications.
*****
Summary of Description:
Please become a member to watch the full episode and gain immediate access to our entire catalog of AMA episodes! Subscribe now: https://bit.ly/3Hfq0kV.
In this “Ask Me Anything” (AMA) episode, Peter and Bob discuss all things related to GLP-1 agonists—a class of drugs that are gaining popularity for treating obesity. They cover the discovery of these peptides, their physiology, and what they do in their natural state. Next, Peter and Bob break down a recently published study that showed remarkable results for weight loss and other metabolic parameters using a once-weekly injection of the GLP-1 agonist drug semaglutide, also known as Ozempic, in overweight and obese patients. Finally, they compare results from the semaglutide study to results from various lifestyle interventions and give their take on the potential future of GLP-1 agonists.
In this sneak peek, we discuss the following:
00:00 – Intro
00:10 – Remarkable results of a recent study in overweight adults
02:15 – Key background on insulin, glucagon, and the incretin effect to appreciate the impact of semaglutide
In the entire episode, we also discuss the following:
-What is GLP-1, and how does it work?
-2021 semaglutide study: remarkable results, side effects, and open questions;
-Semaglutide vs. lifestyle interventions: comparing results with semaglutide vs. lifestyle interventions alone;
-Closing thoughts and open questions on the therapeutic potential of semaglutide; and
-More.
Read the show notes for this episode here: https://bit.ly/3nbZYac.
——–
About:
The Peter Attia Drive is a weekly, ultra-deep-dive podcast focusing on maximizing health, longevity, critical thinking…and a few other things. With over 35 million episodes downloaded, it features topics including fasting, ketosis, Alzheimer’s disease, cancer, mental health, and much more.
Peter is a physician focusing on the applied science of longevity. His practice extensively deals with nutritional interventions, exercise physiology, sleep physiology, emotional and mental health, and pharmacology to increase lifespan (delay the onset of chronic disease) while improving healthspan (quality of life).
Learn more: https://bit.ly/3kBNdUG
Subscribe to receive exclusive subscriber-only content: https://bit.ly/3Hfq0kV
Sign up to receive Peter’s email newsletter: https://bit.ly/30mqvII
Connect with Peter on:
Facebook: http://bit.ly/PeterAttiaMDFB
Twitter: http://bit.ly/PeterAttiaMDTW
Instagram: http://bit.ly/PeterAttiaMDIG
Subscribe to The Drive:
Apple Podcast: http://bit.ly/TheDriveApplePodcasts
Overcast: http://bit.ly/TheDriveOvercast
Spotify: http://bit.ly/TheDriveSpotify
Google Podcasts: http://bit.ly/TheDriveGoogle
*****
Ask Me Anything (AMA) videos are taking YouTube by storm; this latest episode from The Peter Attia Drive is a must-watch for anyone interested in understanding GLP-1 agonists. Hosts Peter and Bob break down everything you need to know about GLP-1 agonists in a way that is easy to digest but still informative.
In this sneak peek, Peter and Bob discuss the remarkable results of a recent study on the GLP-1 agonist drug semaglutide. The study showed impressive weight loss and other metabolic parameters outcomes in overweight and obese patients after one once-weekly injection. To appreciate the effects of semaglutide, Peter and Bob give us critical background on insulin, glucagon, and the incretin effect.
The whole episode delves deeper into topics like GLP-1 and how it works, comparing semaglutide results to lifestyle interventions alone, and closing thoughts on the therapeutic potential of semaglutide.
The Peter Attia Drive podcast is a weekly, ultra-deep-dive series focusing on maximizing health, longevity, critical thinking, and more. With 35 million episodes downloaded, it features topics including fasting, ketosis, Alzheimer’s disease, cancer, mental health, and pharmacology to increase lifespan or delay the onset of chronic illness while improving healthspan.
Peter is a physician who focuses on the applied science of longevity; his practice deals extensively with nutritional interventions, exercise physiology, sleep physiology, emotional and mental health, and pharmacology to increase lifespan while improving healthspan.
The Drive is available on Apple, Overcast, Spotify, and Google Podcasts. To gain immediate access to the entire back catalog of AMA episodes and other exclusive content, become a member by subscribing now. And don’t forget to sign up for Peter’s email newsletter and follow along on Facebook, Twitter, and Instagram.
*****
Source Description
Become a member to watch the full episode, plus gain immediate access to our entire back catalog of AMA episodes! Subscribe now: https://bit.ly/3Hfq0kV.
In this “Ask Me Anything” (AMA) episode, Peter and Bob discuss all things related to GLP-1 agonists—a class of drugs that are gaining popularity for treating obesity. They cover the discovery of these peptides, their physiology, and what they do in their natural state. Next, Peter and Bob break down a recently published study that showed remarkable results for weight loss and other metabolic parameters using a once-weekly injection of the GLP-1 agonist drug semaglutide, also known as Ozempic, in overweight and obese patients. Finally, they compare results from the semaglutide study to results from various lifestyle interventions and give their take on the potential future of GLP-1 agonists.
In this sneak peek, we discuss the following:
00:00 – Intro
00:10 – Remarkable results of a recent study in overweight adults
02:15 – Key background on insulin, glucagon, and the incretin effect to appreciate the impact of semaglutide
In the entire episode, we also discuss the following:
-What is GLP-1, and how does it work?
-2021 semaglutide study: remarkable results, side effects, and open questions;
-Semaglutide vs. lifestyle interventions: comparing results with semaglutide vs. lifestyle interventions alone;
-Closing thoughts and open questions on the therapeutic potential of semaglutide; and
-More.
Read the show notes for this episode here: https://bit.ly/3nbZYac.
——–
About:
The Peter Attia Drive is a weekly, ultra-deep-dive podcast focusing on maximizing health, longevity, critical thinking…and a few other things. With over 35 million episodes downloaded, it features topics including fasting, ketosis, Alzheimer’s disease, cancer, mental health, and much more.
Peter is a physician focusing on the applied science of longevity. His practice extensively deals with nutritional interventions, exercise physiology, sleep physiology, emotional and mental health, and pharmacology to increase lifespan (delay the onset of chronic disease) while improving healthspan (quality of life).
Learn more: https://bit.ly/3kBNdUG
Subscribe to receive exclusive subscriber-only content: https://bit.ly/3Hfq0kV
Sign up to receive Peter’s email newsletter: https://bit.ly/30mqvII
Connect with Peter on:
Facebook: http://bit.ly/PeterAttiaMDFB
Twitter: http://bit.ly/PeterAttiaMDTW
Instagram: http://bit.ly/PeterAttiaMDIG
Subscribe to The Drive:
Apple Podcast: http://bit.ly/TheDriveApplePodcasts
Overcast: http://bit.ly/TheDriveOvercast
Spotify: http://bit.ly/TheDriveSpotify
Google Podcasts: http://bit.ly/TheDriveGoogle
Comments are closed